In an unusual move, ICER rescinds draft report on JAK drugs for rheumatoid arthritis to revise its modeling approach
Two years ago, the Institute for Clinical and Economic Review (ICER) admonished AbbVie for overpricing the best-selling drug in the world — Humira — along with the raft of rival drugs approved for rheumatoid arthritis. On Wednesday, the influential cost-effectiveness watchdog rescinded its draft report on the new crop of JAK inhibitors, saying it was revisiting the modeling approach it employed in the analysis published in late September.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters